This article is more than 5 years old. Information may no longer be current.
ESBATech initiates phase 2a trial of antibody fragment for anterior uveitis
Click Here to Manage Email Alerts
ZURICH, Switzerland — ESBATech has initiated a phase 2a clinical trial evaluating the safety, tolerability and clinical activity of ESBA105 when topically applied in patients with acute, unilateral anterior uveitis, the company announced in a press release.
ESBA105 is a single-chain antibody fragment directed against TNF-alpha, a mediator of inflammation, the release said.
This follows ESBATech's announcement earlier this month of its initiation of a phase 1b/2a study of the antibody fragment therapy in cataract surgery patients.
To coincide with the phase 2a uveitis study, ESBATech has also assembled a six-member clinical advisory board comprising members from the United States, the United Kingdom, Germany, Italy and Japan to help advance the program to completion, according to the release.
"ESBA105 represents a novel approach to treat uveitis," Manfred Zierhut, MD, principal investigator and clinical advisory board member, said in the release. "For the first time it seems possible to administer a biologic therapeutic to patients — without systemic or intravitreal injections — but topically with eye drops."
The trial is being conducted at several uveitis centers in Germany, the release said.